Just Saw some Astra execs in office

Bye bye Shire. FDA fine and takeover are imminent....

Cafepharma: reliable and accurate information you can count on!

http://www.pharmatimes.com/Article/...s_for_US_Clinical_Researcher_of_the_Year.aspx

New quality standards unveiled as entry opens for US Clinical Researcher of the Year
Clinical News | March 29, 2012
Staff Reporter


Senior clinical executives from top pharmaceutical companies, including AstraZeneca, Sanofi, Shire and GSK, met earlier this month at the US offices of Shire Pharmaceuticals to agree the quality standards and define the competencies for a global competition to recognise and encourage talented researchers in North and South America.

The US Clinical Researcher of the Year competition (www.usclinicalresearcher.com) is an important initiative because it provides professionals working within the clinical research fraternity with the opportunity for personal development through a series of peer-mediated and competency-based exercises.

Jim Thomasell, executive director of competition partner and sponsor, the Association of Clinical Research Professionals, notes: “ACRP is delighted to support the US Clinical Researcher of the Year competition, because its aims are very much aligned with our mission, namely to provide leadership to promote integrity and excellence for the clinical research profession.”

The case-study nature of the competition means participants and the organisations supporting them have no concerns over sharing sensitive information regarding their day-to-day work. And, importantly, competitors can test their skills and knowledge to challenge themselves within the protected environment of an industry competition....
 






Cafepharma: reliable and accurate information you can count on!

http://www.pharmatimes.com/Article/...s_for_US_Clinical_Researcher_of_the_Year.aspx

New quality standards unveiled as entry opens for US Clinical Researcher of the Year
Clinical News | March 29, 2012
Staff Reporter


Senior clinical executives from top pharmaceutical companies, including AstraZeneca, Sanofi, Shire and GSK, met earlier this month at the US offices of Shire Pharmaceuticals to agree the quality standards and define the competencies for a global competition to recognise and encourage talented researchers in North and South America.

The US Clinical Researcher of the Year competition (www.usclinicalresearcher.com) is an important initiative because it provides professionals working within the clinical research fraternity with the opportunity for personal development through a series of peer-mediated and competency-based exercises.

Jim Thomasell, executive director of competition partner and sponsor, the Association of Clinical Research Professionals, notes: “ACRP is delighted to support the US Clinical Researcher of the Year competition, because its aims are very much aligned with our mission, namely to provide leadership to promote integrity and excellence for the clinical research profession.”

The case-study nature of the competition means participants and the organisations supporting them have no concerns over sharing sensitive information regarding their day-to-day work. And, importantly, competitors can test their skills and knowledge to challenge themselves within the protected environment of an industry competition....

Sounds like the same BS they told people in Germany when the Nazis were organizing. Look out here it comes ohhhhhnnnnnoooooooo.
 






It is true that AZ is actively looking for M and A but Shire could come at to high a price tag. AZ just lost a patent fight with regular Seroquel and will be losing billions from this and possibly several other patent losses over the next couple years.

The one positive for Shire here is that a buyout would be more than AZ is looking to pay. Reportedly AZ is looking for buyouts in the 10 billion range and Shire is currently valued around 30 billion.

No one knows exactly but it does seem highly unusual to have so many higher level people leave in such a short time frame....

One other possibility for a buyout would be if a suiter saw some of the data on the new potential indications coming that may make the value of our stock much more reasonable as these markets have a huge upside potential..
 












Cafepharma: reliable and accurate information you can count on!

http://www.pharmatimes.com/Article/...s_for_US_Clinical_Researcher_of_the_Year.aspx

New quality standards unveiled as entry opens for US Clinical Researcher of the Year
Clinical News | March 29, 2012
Staff Reporter


Senior clinical executives from top pharmaceutical companies, including AstraZeneca, Sanofi, Shire and GSK, met earlier this month at the US offices of Shire Pharmaceuticals to agree the quality standards and define the competencies for a global competition to recognise and encourage talented researchers in North and South America.

The US Clinical Researcher of the Year competition (www.usclinicalresearcher.com) is an important initiative because it provides professionals working within the clinical research fraternity with the opportunity for personal development through a series of peer-mediated and competency-based exercises.

Jim Thomasell, executive director of competition partner and sponsor, the Association of Clinical Research Professionals, notes: “ACRP is delighted to support the US Clinical Researcher of the Year competition, because its aims are very much aligned with our mission, namely to provide leadership to promote integrity and excellence for the clinical research profession.”

The case-study nature of the competition means participants and the organisations supporting them have no concerns over sharing sensitive information regarding their day-to-day work. And, importantly, competitors can test their skills and knowledge to challenge themselves within the protected environment of an industry competition....

Calling BS, no one would meet at Shire offices to discuss excellence in clinical research since Shire can't complete a successful clinical research trial for something as simple as diverticulitis...